UCB Group's Vimpat(TM) Recommended for Approval in Europe for Epilepsy

BRUSSELS, BELGIUM--(Marketwire - June 26, 2008) - Press release: regulated information UCB announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion recommending that the European Commission grants a marketing authorisation for lacosamide, proposed trade name Vimpat™, for the adjunctive treatment of partial onset seizures with or without secondary generalisation in patients with epilepsy, aged 16 years and older.